TW201808930A - 作為抗癌劑之雜環約束型三環磺醯胺 - Google Patents

作為抗癌劑之雜環約束型三環磺醯胺 Download PDF

Info

Publication number
TW201808930A
TW201808930A TW105129416A TW105129416A TW201808930A TW 201808930 A TW201808930 A TW 201808930A TW 105129416 A TW105129416 A TW 105129416A TW 105129416 A TW105129416 A TW 105129416A TW 201808930 A TW201808930 A TW 201808930A
Authority
TW
Taiwan
Prior art keywords
mmol
group
piperan
tetrahydro
compound according
Prior art date
Application number
TW105129416A
Other languages
English (en)
Chinese (zh)
Inventor
麥可 歐米爾
尼須 札維爾
Original Assignee
美國西奈山伊坎醫學院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美國西奈山伊坎醫學院 filed Critical 美國西奈山伊坎醫學院
Publication of TW201808930A publication Critical patent/TW201808930A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW105129416A 2015-09-09 2016-09-09 作為抗癌劑之雜環約束型三環磺醯胺 TW201808930A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562216172P 2015-09-09 2015-09-09
US62/216,172 2015-09-09

Publications (1)

Publication Number Publication Date
TW201808930A true TW201808930A (zh) 2018-03-16

Family

ID=56936551

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105129416A TW201808930A (zh) 2015-09-09 2016-09-09 作為抗癌劑之雜環約束型三環磺醯胺

Country Status (8)

Country Link
US (1) US10759790B2 (enExample)
EP (1) EP3347355B1 (enExample)
JP (1) JP6955485B2 (enExample)
CN (1) CN108349961B (enExample)
AR (1) AR105975A1 (enExample)
CA (1) CA2997784A1 (enExample)
TW (1) TW201808930A (enExample)
WO (1) WO2017044569A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106458916A (zh) 2014-03-11 2017-02-22 西奈山伊坎医学院 受限制的三环磺酰胺
JP2017512766A (ja) 2014-03-11 2017-05-25 アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ 抗癌剤としてのトリシクリル−２−アミノシクロアルカノール由来スルホンアミド
US10450282B2 (en) * 2015-08-06 2019-10-22 Icahn School Of Medicine At Mount Sinai Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols
EP3347350A1 (en) 2015-09-09 2018-07-18 Icahn School of Medicine at Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
WO2021150697A1 (en) * 2020-01-22 2021-07-29 Icahn School Of Medicine At Mount Sinai N-substituted-3-tricyclyl piperidine derivatives as anticancer and neuroprotective agents
WO2021150700A1 (en) * 2020-01-22 2021-07-29 Icahn School Of Medicine At Mount Sinai N-substituted-3-tricyclyl piperidine derivatives as anticancer and neuroprotective agents
CN112778257A (zh) * 2021-01-21 2021-05-11 香港科技大学 一种将糠醇氧化为二氢吡喃酮类衍生物的绿色方法
CN116806217A (zh) * 2021-02-08 2023-09-26 拉帕塔疗法公司 蛋白磷酸酶2a(pp2a)的取代的环状调节剂及其使用方法
KR20230145089A (ko) * 2021-02-08 2023-10-17 랍타 테라퓨틱스 오와이 단백질 포스파타제 2a(pp2a)의 치환된 사이클릭 조절인자 및 이를 사용하는 방법
EP4543863A1 (en) * 2022-06-23 2025-04-30 University Of Ottawa Ferroptosis inhibitors and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634766A (en) 1983-10-31 1987-01-06 Merck Frosst Canada, Inc. 1,4-diaza-phenothiazines
GB8510680D0 (en) 1985-04-26 1985-06-05 Smith Kline French Lab Pyridine derivatives
US4882351A (en) 1987-10-14 1989-11-21 Roussel Uclaf Tricyclic compounds
WO1995003279A1 (en) 1993-07-26 1995-02-02 Eisai Co., Ltd. Sulfonamide and sulfonic ester derivatives each having tricyclic hetero ring
EP0881220A4 (en) 1996-02-15 1999-04-21 Mitsubishi Chem Corp DIARYLSULTAME DERIVATIVES
US6333322B1 (en) 1996-03-13 2001-12-25 Eisai Co., Ltd. Nitrogen-containing tricyclic compounds and drugs containing the same
AU2641899A (en) 1998-02-27 1999-09-15 Eisai Co. Ltd. Heterocycle-fused benzothiazine derivatives
AU2001291040A1 (en) 2000-09-20 2002-04-02 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
EP1481673A4 (en) 2002-02-05 2008-09-24 Ajinomoto Kk MEDICAL COMPOSITIONS WITH GABAPENTIN OR PREGABALINE AND N-TYPE CALCIUM CHANNEL ANTAGONIST
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
KR20070092297A (ko) 2004-12-21 2007-09-12 데브젠 엔브이 Ｋｖ4 이온 채널 활성을 갖는 화합물
IT1362675B (it) 2005-03-15 2009-06-25 Menarini Internat Operations Luxembourg Sa N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
CN101277949A (zh) 2005-04-22 2008-10-01 阿兰托斯制药控股公司 二肽基肽酶-ⅳ抑制剂
GB0508992D0 (en) 2005-05-03 2005-06-08 Novartis Ag Organic compounds
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
WO2008121859A1 (en) 2007-03-30 2008-10-09 Xenon Pharmaceuticals Inc. Methods of using tricyclic compounds in treating sodium channel-mediated diseases or conditions
AU2012253759B2 (en) * 2011-05-06 2016-01-21 Zafgen Inc. Tricyclic sulfonamide compounds and methods of making and using same
JP6105585B2 (ja) * 2011-08-16 2017-03-29 アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ 抗腫瘍剤としての三環式化合物
AU2013305591B2 (en) 2012-08-24 2017-04-13 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CN102942562B (zh) 2012-12-05 2014-10-01 天津市斯芬克司药物研发有限公司 一种苯并咪唑衍生物及其制备方法和应用
CN105073117A (zh) * 2013-02-19 2015-11-18 西奈山伊坎医学院 作为抗癌剂的三环杂环化合物
CN106458916A (zh) 2014-03-11 2017-02-22 西奈山伊坎医学院 受限制的三环磺酰胺
JP2017512766A (ja) * 2014-03-11 2017-05-25 アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ 抗癌剤としてのトリシクリル−２−アミノシクロアルカノール由来スルホンアミド
US10450282B2 (en) 2015-08-06 2019-10-22 Icahn School Of Medicine At Mount Sinai Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols
EP3347350A1 (en) 2015-09-09 2018-07-18 Icahn School of Medicine at Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
WO2017044571A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Tricyclic sultam sulfonamides as anticancer and neuroprotective agents
WO2017044575A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Constrained benzhydryl sulfonamides as anticancer and neuroprotective agents
WO2017044572A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Ring constrained diarylamino sulfonamides as anti-cancer agents

Also Published As

Publication number Publication date
EP3347355B1 (en) 2022-07-13
CN108349961B (zh) 2022-02-18
JP6955485B2 (ja) 2021-10-27
EP3347355A1 (en) 2018-07-18
CA2997784A1 (en) 2017-03-16
JP2018526419A (ja) 2018-09-13
WO2017044569A1 (en) 2017-03-16
CN108349961A (zh) 2018-07-31
US20180251456A1 (en) 2018-09-06
US10759790B2 (en) 2020-09-01
HK1259348A1 (zh) 2019-11-29
AR105975A1 (es) 2017-11-29

Similar Documents

Publication Publication Date Title
CN108349961B (zh) 杂环受限三环磺酰胺作为抗癌试剂
JP7584815B2 (ja) 抗腫瘍薬物における芳香族化合物及びその用途
JP6966425B2 (ja) 抗がん剤としての複素環式の限定された三環系スルホンアミド
TWI543961B (zh) Novel hydroxamic acid derivatives
CN105916855A (zh) 作为酪蛋白激酶1d/e抑制剂的取代的4,5,6,7-四氢吡唑并[1,5-a]吡嗪衍生物
JP2020532506A (ja) 化合物、組成物、及び、方法
WO2013033268A2 (en) Bivalent bromodomain ligands, and methods of using same
EP3116860B1 (en) Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents
WO2017044575A1 (en) Constrained benzhydryl sulfonamides as anticancer and neuroprotective agents
CN105008370B (zh) 作为cftr抑制剂的三环化合物
CN105026375B (zh) Ship1调节剂和与其相关的方法
WO2017044571A1 (en) Tricyclic sultam sulfonamides as anticancer and neuroprotective agents
EP3160965A1 (en) 3-substituted 2-amino-indole derivatives
CN107922353A (zh) Ido抑制剂
CN114502533A (zh) 苯磺酰胺衍生物及其用途
CN118076610A (zh) 具有ent1抑制活性的大环化合物
KR20230166084A (ko) Abhd6 안타고니스트
CN111801333A (zh) 作为正粘病毒复制抑制剂用于治疗流感的10-(二(苯基)甲基)-4-羟基-8,9,9a,10-四氢-7H-吡咯并[1’,2’:4,5]吡嗪并[1,2-b]哒嗪-3,5-二酮衍生物及相关化合物
WO2019129114A1 (zh) 吲哚胺2,3-双加氧酶抑制剂以及它们在医学上的应用
TW202220999A (zh) 作為造血前驅細胞激酶１（ｈｐｋ１）抑制劑的吲唑及其使用方法
HK1259348B (en) Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
TWI923885B (zh) 含五元雜芳環結構化合物、其藥物組合物及應用
CN104619707A (zh) 稠环杂环化合物
TW202517241A (zh) 囊腫纖維化跨膜傳導調節蛋白之調節劑
CN119192202A (zh) 含磷或含硫的大环吡唑并嘧啶类化合物及其用途